Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsBy Nathan Reiff. First Published: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Have $500? Invest in Elon's AI Masterplan
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Several promising treatments have shown strong potential—and with that comes the possibility of significant sales. Two smaller biotech companies are experiencing meaningful share-price momentum thanks to their leading oncology medicines. Besides offering powerful treatment potential, these drugs may help the firms move toward greater stability beyond penny-stock or otherwise unstable status, and potentially toward long-term profitability. In both cases, challenges remain, making them typical high-risk biotech investments that also offer the possibility of outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Oil is soaring, but today America's trading partners are exchanging their dollars for gold, not the other way around—don't believe me? Then you need to explain why gold is now America's largest export. I'm Garrett Goggin, America's leading gold analyst with 25 years experience finding gold stocks before they take off, and today I'm outlining the next 5X company you need to own now. I found a company that just produced its first gold, and on May 20th, this company will post its first revenues—until a company posts its first revenue, Wall Street and Main Street ignore mining stocks, which is why today my favorite gold stock is a small miner that just produced its first gold. Click here for the free gold stock report before May revenues hit Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 slipped about 1%. That added to IOVA's year-to-date (YTD) gains, which have more than doubled so far. Still, with a consensus price target of $8.88, Wall Street expects more from IOVA shares—that target implies roughly 71% further upside from current levels. The main catalyst for Iovance's rally is its lead drug, Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States since 2024 and is building momentum in sales and regulatory progress, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could reach more than $1 billion in U.S. peak sales. Amtagvi's potential may extend beyond melanoma: the drug received FDA Fast Track Designation for non-small cell lung cancer and could be effective against additional cancers. Some of Iovance's outperformance this year also reflects its Q4 2025 earnings report, issued in late February, in which the company posted a smaller-than-expected loss per share and $5 million in revenue. For the full year, revenue rose about 30% year-over-year (YOY). Iovance remains a relatively small biotech (about $2 billion market cap) that has traded at low share prices. Despite this year's rally, analysts are cautious: roughly half of its roughly 12 ratings are Hold or Sell. Risks remain high—beyond the usual caveats for smaller biotechs, Iovance's manufacturing process for Amtagvi is complex and costly because the therapy is personalized. That could limit margins and hinder profitability even as demand increases. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) has dipped about 20% in March, but its year-to-date performance dwarfs Iovance's: IBRX shares are up nearly 300% in 2026 alone, and that may be just the beginning. Analysts' consensus price target of $13.60 implies roughly 70% upside from the stock's current price even after this major run-up. ImmunityBio's leading product and primary growth driver is Anktiva, a treatment for certain types of bladder cancer. In February, shares spiked after the E.U. regulator granted the drug conditional marketing authorization—the latest in a series of approvals worldwide. Anktiva is driving the firm's revenue performance, generating $113 million in sales last year — roughly a 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in other cancer types, and ImmunityBio is actively exploring additional indications. Despite this surge, IBRX remains a speculative and risky investment. IBRX reported a full-year net loss of $351 million for 2025 as R&D spending remains high. Wall Street analysts are relatively bullish, however: six of seven rate the stock as a Buy or equivalent. | 
